SCYNEXIS Announces Results From Second Interim Analysis Of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability To Treat Severe Fungal Infections In The Hospital Setting
Benzinga Newsdesk